Arich Enterprise Co Ltd (4173) - Total Liabilities

Latest as of December 2025: NT$3.25 Billion TWD ≈ $102.34 Million USD

Based on the latest financial reports, Arich Enterprise Co Ltd (4173) has total liabilities worth NT$3.25 Billion TWD (≈ $102.34 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 4173 cash flow conversion to assess how effectively this company generates cash.

Arich Enterprise Co Ltd - Total Liabilities Trend (2017–2025)

This chart illustrates how Arich Enterprise Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Arich Enterprise Co Ltd to evaluate the company's liquid asset resilience ratio.

Arich Enterprise Co Ltd Competitors by Total Liabilities

The table below lists competitors of Arich Enterprise Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
flyExclusive, Inc.
NYSE:FLYX
USA $496.04 Million
FNC ADD CULTURE. Co. Ltd
KQ:063440
Korea ₩5.94 Billion
Public Packages Holdings Bhd
KLSE:8273
Malaysia RM38.35 Million
Black Canyon Ltd
AU:BCA
Australia AU$327.82K
FoundPac Group Bhd
KLSE:5277
Malaysia RM46.62 Million
FFI Holdings Ltd
AU:FFI
Australia AU$20.81 Million
Kinatico Ltd
AU:KYP
Australia AU$6.19 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Arich Enterprise Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Arich Enterprise Co Ltd market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.44 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.61 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.62 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Arich Enterprise Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Arich Enterprise Co Ltd (2017–2025)

The table below shows the annual total liabilities of Arich Enterprise Co Ltd from 2017 to 2025.

Year Total Liabilities Change
2025-12-31 NT$3.25 Billion
≈ $102.34 Million
-37.33%
2024-12-31 NT$5.18 Billion
≈ $163.30 Million
+43.95%
2023-12-31 NT$3.60 Billion
≈ $113.44 Million
+17.62%
2022-12-31 NT$3.06 Billion
≈ $96.45 Million
+14.62%
2021-12-31 NT$2.67 Billion
≈ $84.14 Million
+23.24%
2020-12-31 NT$2.17 Billion
≈ $68.28 Million
-13.15%
2019-12-31 NT$2.50 Billion
≈ $78.62 Million
-28.75%
2018-12-31 NT$3.50 Billion
≈ $110.34 Million
-18.10%
2017-12-31 NT$4.28 Billion
≈ $134.72 Million
--

About Arich Enterprise Co Ltd

TWO:4173 Taiwan Pharmaceutical Retailers
Market Cap
$44.52 Million
NT$1.41 Billion TWD
Market Cap Rank
#22321 Global
#1384 in Taiwan
Share Price
NT$18.95
Change (1 day)
-0.52%
52-Week Range
NT$18.95 - NT$25.35
All Time High
NT$27.40
About

Arich Enterprise Co., Ltd. engages in the marketing, promotion, and distribution of pharmaceuticals in Taiwan. It offers sales promotion services for prescription and instruction medications, and health consumer products; and warehousing and distribution logistics services for prescription and instruction medications, controlled drugs, cold chain products, clinical trial products, consumer health… Read more